vs

Side-by-side financial comparison of CAMDEN NATIONAL CORP (CAC) and OptimizeRx Corp (OPRX). Click either name above to swap in a different company.

CAMDEN NATIONAL CORP is the larger business by last-quarter revenue ($64.3M vs $32.2M, roughly 2.0× OptimizeRx Corp). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs 15.6%, a 18.4% gap on every dollar of revenue. Over the past eight quarters, OptimizeRx Corp's revenue compounded faster (28.0% CAGR vs 22.6%).

Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.

OptimizeRx Corp is a U.S.-headquartered digital health technology company that delivers patient engagement, medication affordability and clinical communication solutions to life sciences enterprises, healthcare providers and pharmacy partners. Its core offerings include digital medication savings tools, patient support programs, and therapeutic area-specific resources to boost medication access and treatment adherence.

CAC vs OPRX — Head-to-Head

Bigger by revenue
CAC
CAC
2.0× larger
CAC
$64.3M
$32.2M
OPRX
Higher net margin
CAC
CAC
18.4% more per $
CAC
34.0%
15.6%
OPRX
Faster 2-yr revenue CAGR
OPRX
OPRX
Annualised
OPRX
28.0%
22.6%
CAC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CAC
CAC
OPRX
OPRX
Revenue
$64.3M
$32.2M
Net Profit
$21.9M
$5.0M
Gross Margin
74.8%
Operating Margin
26.6%
Net Margin
34.0%
15.6%
Revenue YoY
-0.2%
Net Profit YoY
6535.9%
EPS (diluted)
$1.29
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAC
CAC
OPRX
OPRX
Q1 26
$64.3M
Q4 25
$68.1M
$32.2M
Q3 25
$65.4M
$26.1M
Q2 25
$62.3M
$29.2M
Q1 25
$60.1M
$21.9M
Q4 24
$47.6M
$32.3M
Q3 24
$45.0M
$21.3M
Q2 24
$42.8M
$18.8M
Net Profit
CAC
CAC
OPRX
OPRX
Q1 26
$21.9M
Q4 25
$22.6M
$5.0M
Q3 25
$21.2M
$779.0K
Q2 25
$14.1M
$1.5M
Q1 25
$7.3M
$-2.2M
Q4 24
$14.7M
$-78.0K
Q3 24
$13.1M
$-9.1M
Q2 24
$12.0M
$-4.0M
Gross Margin
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
74.8%
Q3 25
67.2%
Q2 25
63.8%
Q1 25
60.9%
Q4 24
68.1%
Q3 24
63.1%
Q2 24
62.2%
Operating Margin
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
41.5%
26.6%
Q3 25
40.5%
7.9%
Q2 25
28.5%
10.9%
Q1 25
10.3%
-9.6%
Q4 24
38.7%
11.2%
Q3 24
35.2%
-40.2%
Q2 24
34.7%
-19.9%
Net Margin
CAC
CAC
OPRX
OPRX
Q1 26
34.0%
Q4 25
33.1%
15.6%
Q3 25
32.4%
3.0%
Q2 25
22.6%
5.2%
Q1 25
12.2%
-10.0%
Q4 24
30.8%
-0.2%
Q3 24
29.1%
-42.8%
Q2 24
28.0%
-21.3%
EPS (diluted)
CAC
CAC
OPRX
OPRX
Q1 26
$1.29
Q4 25
$1.33
$0.27
Q3 25
$1.25
$0.04
Q2 25
$0.83
$0.08
Q1 25
$0.43
$-0.12
Q4 24
$1.00
$0.00
Q3 24
$0.90
$-0.50
Q2 24
$0.81
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAC
CAC
OPRX
OPRX
Cash + ST InvestmentsLiquidity on hand
$23.4M
Total DebtLower is stronger
$514.4M
$26.3M
Stockholders' EquityBook value
$710.0M
$128.3M
Total Assets
$7.0B
$176.9M
Debt / EquityLower = less leverage
0.72×
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
$23.4M
Q3 25
$19.5M
Q2 25
$16.6M
Q1 25
$16.6M
Q4 24
$13.4M
Q3 24
$16.1M
Q2 24
Total Debt
CAC
CAC
OPRX
OPRX
Q1 26
$514.4M
Q4 25
$26.3M
Q3 25
$28.8M
Q2 25
$29.3M
Q1 25
$33.8M
Q4 24
$34.3M
Q3 24
$36.8M
Q2 24
$37.3M
Stockholders' Equity
CAC
CAC
OPRX
OPRX
Q1 26
$710.0M
Q4 25
$696.6M
$128.3M
Q3 25
$676.4M
$122.3M
Q2 25
$652.1M
$119.3M
Q1 25
$640.1M
$116.3M
Q4 24
$531.2M
$117.0M
Q3 24
$529.9M
$114.5M
Q2 24
$508.3M
$121.0M
Total Assets
CAC
CAC
OPRX
OPRX
Q1 26
$7.0B
Q4 25
$7.0B
$176.9M
Q3 25
$7.0B
$170.3M
Q2 25
$6.9B
$169.3M
Q1 25
$7.0B
$167.8M
Q4 24
$5.8B
$171.2M
Q3 24
$5.7B
$165.2M
Q2 24
$5.7B
$172.9M
Debt / Equity
CAC
CAC
OPRX
OPRX
Q1 26
0.72×
Q4 25
0.20×
Q3 25
0.24×
Q2 25
0.25×
Q1 25
0.29×
Q4 24
0.29×
Q3 24
0.32×
Q2 24
0.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAC
CAC
OPRX
OPRX
Operating Cash FlowLast quarter
$7.1M
Free Cash FlowOCF − Capex
$7.1M
FCF MarginFCF / Revenue
22.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.41×
TTM Free Cash FlowTrailing 4 quarters
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
$63.9M
$7.1M
Q3 25
$36.1M
$3.2M
Q2 25
$6.0M
$4.6M
Q1 25
$1.0M
$3.9M
Q4 24
$60.9M
$198.0K
Q3 24
$-14.5M
$1.8M
Q2 24
$14.5M
$782.0K
Free Cash Flow
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
$58.2M
$7.1M
Q3 25
$35.4M
$3.2M
Q2 25
$4.5M
$4.6M
Q1 25
$-727.0K
$3.8M
Q4 24
$55.4M
$181.0K
Q3 24
$-16.2M
$1.8M
Q2 24
$13.2M
$737.0K
FCF Margin
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
85.5%
22.0%
Q3 25
54.1%
12.2%
Q2 25
7.3%
15.6%
Q1 25
-1.2%
17.5%
Q4 24
116.4%
0.6%
Q3 24
-36.0%
8.3%
Q2 24
30.8%
3.9%
Capex Intensity
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
8.4%
0.0%
Q3 25
1.1%
0.0%
Q2 25
2.4%
0.0%
Q1 25
2.9%
0.1%
Q4 24
11.7%
0.1%
Q3 24
3.8%
0.1%
Q2 24
3.0%
0.2%
Cash Conversion
CAC
CAC
OPRX
OPRX
Q1 26
Q4 25
2.83×
1.41×
Q3 25
1.70×
4.11×
Q2 25
0.43×
2.98×
Q1 25
0.14×
Q4 24
4.15×
Q3 24
-1.11×
Q2 24
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CAC
CAC

Net Interest Income$52.4M81%
Noninterest Income$12.0M19%

OPRX
OPRX

Segment breakdown not available.

Related Comparisons